{"id":"positive-control-vaccine-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Positive control vaccines are used in vaccine development studies to validate trial methodology and demonstrate that the study population can mount appropriate immune responses. This vaccine serves as a benchmark to compare the immunogenicity and safety profile of investigational vaccine candidates against a known, established vaccine control.","oneSentence":"A positive control vaccine designed to elicit immune responses as a reference standard in clinical trials.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:29:42.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial positive control (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT07372950","phase":"NA","title":"Kaiser Colorado Flu Nudge","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaiser Permanente","startDate":"2025-10-06","conditions":"Influenza, Vaccination","enrollment":100000},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":"Malaria, Malaria Vaccine, Insecticide-treated Bednets","enrollment":1691},{"nctId":"NCT06932523","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-04-04","conditions":"Herpes Zoster (HZ)","enrollment":645},{"nctId":"NCT07324356","phase":"NA","title":"Effects of Individual and Group Education on Mothers' Attitudes and Decisions About Childhood Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2025-11-15","conditions":"Childhood Immunization","enrollment":75},{"nctId":"NCT05595486","phase":"NA","title":"Baby2Home (B2H) Mobile Health Application","status":"COMPLETED","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2022-11-09","conditions":"COVID-19 Pandemic, Health Knowledge, Attitudes, Practice, Perinatal Depression","enrollment":642},{"nctId":"NCT07311148","phase":"PHASE2","title":"A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-23","conditions":"Herpes Zoster (HZ), Shingles, VZV","enrollment":840},{"nctId":"NCT07300644","phase":"PHASE2","title":"Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-11-25","conditions":"Pneumococcal Infectious Disease","enrollment":420},{"nctId":"NCT07297186","phase":"PHASE3","title":"Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2017-08-21","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT06756269","phase":"PHASE2","title":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","status":"RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2025-01-15","conditions":"HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia","enrollment":330},{"nctId":"NCT07285265","phase":"PHASE1","title":"Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-05-27","conditions":"Varicella-zoster Virus","enrollment":180},{"nctId":"NCT06855836","phase":"NA","title":"Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-03-03","conditions":"Overdose","enrollment":588},{"nctId":"NCT04083950","phase":"EARLY_PHASE1","title":"Induction of Gut Permeability by an Oral Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"USDA, Western Human Nutrition Research Center","startDate":"2019-12-04","conditions":"Intestinal Permeability, Inflammation, Vaccine","enrollment":10},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT07122661","phase":"","title":"STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-08-11","conditions":"Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus, Lower Respiratory Tract Disease","enrollment":1},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT06647654","phase":"","title":"Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-08-26","conditions":"Respiratory Syncytial Virus, Respiratory Tract Diseases","enrollment":1},{"nctId":"NCT03376477","phase":"PHASE2","title":"Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-09-23","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT06243666","phase":"","title":"Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2024-02-20","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection","enrollment":2188},{"nctId":"NCT06577298","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-19","conditions":"Poliomyelitis","enrollment":480},{"nctId":"NCT07035054","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2024-04-20","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":992},{"nctId":"NCT07025876","phase":"EARLY_PHASE1","title":"PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-11-18","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":240},{"nctId":"NCT06714513","phase":"PHASE1","title":"ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74","status":"RECRUITING","sponsor":"Quratis Inc.","startDate":"2025-05-09","conditions":"Tuberculosis, Pulmonary","enrollment":144},{"nctId":"NCT06843317","phase":"PHASE1","title":"Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults","status":"RECRUITING","sponsor":"Clover Biopharmaceuticals USA, LLC","startDate":"2025-03-21","conditions":"RSV Infection","enrollment":160},{"nctId":"NCT04078269","phase":"PHASE1","title":"MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-08-26","conditions":"Non-small Cell Lung Cancer","enrollment":6},{"nctId":"NCT06306196","phase":"PHASE2","title":"Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2024-04-04","conditions":"Hepatitis E Virus Infection","enrollment":1040},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT06874842","phase":"PHASE1","title":"Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older","status":"RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-03-13","conditions":"Herpes Zoster (HZ)","enrollment":92},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT06442241","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-07-31","conditions":"Respiratory Syncytial Virus (RSV), RSV Infection","enrollment":84},{"nctId":"NCT06335849","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-03-27","conditions":"Herpes Zoster","enrollment":48},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT06800950","phase":"PHASE3","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-02-08","conditions":"Influenza, Human, Influenza, Human Prevention, Influenza a","enrollment":4400},{"nctId":"NCT06622590","phase":"PHASE1","title":"Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-10-13","conditions":"Influenza, Human, Influenza a, Influenza Type B","enrollment":180},{"nctId":"NCT06752174","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2023-03-08","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT05636436","phase":"PHASE1","title":"Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2022-12-07","conditions":"Herpes Zoster","enrollment":132},{"nctId":"NCT05856084","phase":"PHASE2","title":"Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-05-07","conditions":"Herpes Zoster","enrollment":924},{"nctId":"NCT02938442","phase":"PHASE1, PHASE2","title":"Vaccination of Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2019-01-25","conditions":"Triple Negative Breast Cancer, Breast Neoplasms","enrollment":16},{"nctId":"NCT05978037","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-08-18","conditions":"Malaria, Malaria,Falciparum, Parasitic Disease","enrollment":58},{"nctId":"NCT05216510","phase":"PHASE1","title":"Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens","status":"TERMINATED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2022-01-07","conditions":"Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2","enrollment":9},{"nctId":"NCT05808166","phase":"PHASE2","title":"Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2024-05-02","conditions":"Hepatitis E Infection","enrollment":2358},{"nctId":"NCT03926728","phase":"PHASE1","title":"Safety and Immunogenicity of a Chlamydia Vaccine CTH522","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2020-02-17","conditions":"Trachoma","enrollment":65},{"nctId":"NCT06548139","phase":"PHASE2","title":"Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2024-07-31","conditions":"Rabies Virus Infection","enrollment":120},{"nctId":"NCT04661579","phase":"PHASE2","title":"Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy","status":"COMPLETED","sponsor":"PATH","startDate":"2020-11-06","conditions":"Plasmodium Falciparum","enrollment":620},{"nctId":"NCT04422366","phase":"PHASE3","title":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","status":"RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2020-04-28","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":8000},{"nctId":"NCT05252715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-18","conditions":"Meningitis, Meningococcal","enrollment":1200},{"nctId":"NCT06314659","phase":"PHASE3","title":"Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-17","conditions":"Healthy Population","enrollment":630},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT06314685","phase":"PHASE3","title":"Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-10","conditions":"Healthy Population","enrollment":2450},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT06196502","phase":"NA","title":"The Effect of Gentle Human Touch and Kangaroo Care on Pain and Crying Physiological Parameters During Hepatitis-B Vaccination in a Newborn","status":"UNKNOWN","sponsor":"Kirsehir Ahi Evran Universitesi","startDate":"2024-02-01","conditions":"Pain","enrollment":80},{"nctId":"NCT05284812","phase":"PHASE2","title":"A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)","status":"SUSPENDED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-02-10","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT06088745","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine","status":"RECRUITING","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-09-28","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":4},{"nctId":"NCT05663086","phase":"PHASE2","title":"Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2023-01-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT04364035","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients","status":"COMPLETED","sponsor":"Aelix Therapeutics","startDate":"2020-02-20","conditions":"HIV/AIDS","enrollment":50},{"nctId":"NCT05913024","phase":"PHASE2","title":"Immunogenicity and Safety of Enterovirus Type 71 Vaccine,Inactivated(Vero Cells) in Volunteers Aged From 6 to 71 Months","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-10-19","conditions":"Healthy Volunteers","enrollment":470},{"nctId":"NCT05832073","phase":"EARLY_PHASE1","title":"Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2023-04-30","conditions":"Rabies Virus Infection","enrollment":152},{"nctId":"NCT05323461","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-05-30","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":1800},{"nctId":"NCT02933281","phase":"PHASE1, PHASE2","title":"MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa","status":"COMPLETED","sponsor":"International AIDS Vaccine Initiative","startDate":"2018-05-14","conditions":"Tuberculosis","enrollment":144},{"nctId":"NCT05217563","phase":"NA","title":"Reframing Needle-related Pain","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2022-02-01","conditions":"Pain, Procedural","enrollment":77},{"nctId":"NCT05045755","phase":"","title":"The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-04-13","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":1339},{"nctId":"NCT04969445","phase":"","title":"The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-03-30","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":647},{"nctId":"NCT05394012","phase":"PHASE1","title":"A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19","status":"UNKNOWN","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2022-12","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04100772","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-05-18","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":237},{"nctId":"NCT04099303","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-28","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":400},{"nctId":"NCT05212623","phase":"PHASE1","title":"A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-10-26","conditions":"Influenza","enrollment":120},{"nctId":"NCT04001322","phase":"NA","title":"Tunatar da ni. The Immunization Reminder and Information SMS System (IRISS)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-06-15","conditions":"Low Immunization Uptake","enrollment":21},{"nctId":"NCT02002182","phase":"PHASE2","title":"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer","status":"COMPLETED","sponsor":"Andrew Sikora","startDate":"2013-12","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT05150496","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-15","conditions":"COVID-19","enrollment":640},{"nctId":"NCT04810117","phase":"","title":"Monitoring the IgG/IgM Antibodies in COVID-19 Patients","status":"COMPLETED","sponsor":"University of Sargodha","startDate":"2021-06-15","conditions":"COVID-19 Infections","enrollment":373},{"nctId":"NCT03947775","phase":"PHASE2","title":"HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-09-01","conditions":"Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus","enrollment":228},{"nctId":"NCT05396573","phase":"PHASE1","title":"A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19","status":"UNKNOWN","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2022-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04148118","phase":"PHASE1","title":"A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"BlueWillow Biologics","startDate":"2020-01-08","conditions":"Anthrax","enrollment":84},{"nctId":"NCT05238649","phase":"PHASE2","title":"Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-10","conditions":"COVID-19 Pandemic","enrollment":150},{"nctId":"NCT05284851","phase":"PHASE2","title":"The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2022-04-01","conditions":"Influenza Prevention","enrollment":2520},{"nctId":"NCT02564523","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-11-06","conditions":"Hemorrhagic Fever, Ebola","enrollment":1075},{"nctId":"NCT05238454","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-03-20","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":600},{"nctId":"NCT04425291","phase":"PHASE3","title":"Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","status":"COMPLETED","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2020-05-28","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":1680},{"nctId":"NCT04533399","phase":"PHASE2","title":"A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-08-17","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":4422},{"nctId":"NCT05244356","phase":"NA","title":"Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation","status":"COMPLETED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2021-04-29","conditions":"COVID-19, Respiratory Disease, Vaccine Refusal","enrollment":5784},{"nctId":"NCT01312389","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2011-04","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":3},{"nctId":"NCT00005758","phase":"PHASE3","title":"Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":472},{"nctId":"NCT05060484","phase":"PHASE2","title":"A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2021-10-19","conditions":"Interventional, Prevention, Randomized","enrollment":1800},{"nctId":"NCT03956329","phase":"NA","title":"Flu and Mood in Older Adults","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2019-08-12","conditions":"Vaccination, Infection","enrollment":654},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT01540474","phase":"PHASE1","title":"Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-02","conditions":"Malaria","enrollment":36},{"nctId":"NCT04082182","phase":"PHASE1","title":"MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"University Hospital, Ghent","startDate":"2019-08-26","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":7},{"nctId":"NCT04444674","phase":"PHASE1, PHASE2","title":"COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2020-06-24","conditions":"Coronavirus","enrollment":2130},{"nctId":"NCT04357522","phase":"PHASE3","title":"Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2020-07","conditions":"Pneumonia, Pneumococcal","enrollment":1950},{"nctId":"NCT04278248","phase":"PHASE3","title":"Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2018-01-12","conditions":"Pneumonia, Pneumococcal","enrollment":1940},{"nctId":"NCT01755598","phase":"PHASE2","title":"Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-19","conditions":"Tuberculosis, Tuberculosis Vaccines","enrollment":3575},{"nctId":"NCT00991224","phase":"PHASE1","title":"Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-11","conditions":"HIV Infections","enrollment":2},{"nctId":"NCT00869778","phase":"PHASE2","title":"Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B","status":"COMPLETED","sponsor":"Chongqing Jiachen Biotechnology Ltd.","startDate":"2009-04","conditions":"Chronic Hepatitis B","enrollment":360},{"nctId":"NCT03144518","phase":"NA","title":"Mood and Influenza Vaccine Response: A Feasibility Trial","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2017-09-01","conditions":"Vaccination; Infection","enrollment":106},{"nctId":"NCT01892345","phase":"PHASE3","title":"A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2014-04-11","conditions":"Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder","enrollment":143}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Positive control vaccine 2","genericName":"Positive control vaccine 2","companyName":"Jiangsu Province Centers for Disease Control and Prevention","companyId":"jiangsu-province-centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"A positive control vaccine designed to elicit immune responses as a reference standard in clinical trials. Used for Clinical trial positive control (specific indication unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}